This Program Project Grant proposal addresses personalized medicine - health care targeting medical interventions to patients based on their individual characteristics, particularly their genetics. Our objective is to use an integrated, interdisciplinary approach to obtain evidence about key aspects of the translation of genomic information for breast and colorectal cancer into clinical practice and health policy. Our Program includes four Projects and two Cores with the Specific Aims to:
Aim 1 : Determine utilization of genomic risk stratification and targeted treatment by using the examples of gene expression profiling (GEP) and HER2/neu testing for trastuzumab (Herceptin(r)) for breast cancer.
Aim 2 : Develop an understanding of preferences for genomic testing and interventions using the example of Lynch-syndrome screening.
Aim 3 : Develop a generalized, flexible model for evaluating the cost-effectiveness of personalized medicine and estimate the cost-effectiveness of GEP, HER2/neu testing for trastuzumab, and Lynch syndrome screening using unique data from our Program Projects.
Aim 4 : Develop an evidence base for translating research findings into practice and policy by collecting and synthesizing data on the clinical applications and the regulatory, policy, and economic impacts of genetically based colorectal and breast cancer interventions.
Aim 5 : Provide Projects with resources for: conceptualizing, measuring, and investigating population differences;conducting qualitative and quantitative research;identifying and obtaining data sources; coordinating activities;and disseminating findings. The significance of this proposal lies in our goal to establish evidence-based information that will be useful to patients, clinicians, providers, researchers, and policymakers in assessing how personalized medicine can be most beneficial and efficient. Our results will have implications beyond the specific cancers studied, as the issues related to utilization, access, preferences, economics, value, and policy implications are relevant across cancer sites and interventions.
|Phillips, Kathryn A; Deverka, Patricia A; Sox, Harold C et al. (2017) Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med 19:1081-1091|
|Knight, Sara J; Mohamed, Ateesha F; Marshall, Deborah A et al. (2015) Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Med Decis Making :|
|Ponce, Ninez A; Ko, Michelle; Liang, Su-Ying et al. (2015) Early diffusion of gene expression profiling in breast cancer patients associated with areas of high income inequality. Health Aff (Millwood) 34:609-15|
|Phillips, Kathryn A; Labno, Anna (2014) Private Companies Providing Health Care Price Data: Who Are They and What Information do They Provide? J Manag Care Med 17:75-80|
|Pletcher, Mark J; Pignone, Michael; Earnshaw, Stephanie et al. (2014) Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis. Circ Cardiovasc Qual Outcomes 7:276-84|
|Kilambi, Vikram; Johnson, F Reed; González, Juan Marcos et al. (2014) Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. Value Health 17:838-45|
|Phillips, Kathryn A; Ann Sakowski, Julie; Trosman, Julia et al. (2014) The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 16:251-7|
|Ferrusi, Ilia L; Earle, Craig C; Trudeau, Maureen et al. (2013) Closing the personalized medicine information gap: HER2 test documentation practice. Am J Manag Care 19:838-44|
|Kuppermann, Miriam; Wang, Grace; Wong, Shirley et al. (2013) Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome. Cancer 119:215-25|
|Weitzel, Jeffrey N; Clague, Jessica; Martir-Negron, Arelis et al. (2013) Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol 31:210-6|
Showing the most recent 10 out of 43 publications